To include your compound in the COVID-19 Resource Center, submit it here.

QIMR reports updated Phase I data for MS candidate

Atara Biotherapeutics Inc. (NASDAQ:ATRA) said QIMR Berghofer Medical Research Institute (Brisbane, Australia) reported updated data from a Phase I trial in 10 patients with primary progressive multiple sclerosis (PPMS) and

Read the full 306 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE